DelveInsight's "Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Relapsed/Refractory Acute Myeloid Leukemia market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The report covers emerging Relapsed/Refractory Acute Myeloid Leukemia drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Relapsed/Refractory Acute Myeloid Leukemia treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Relapsed/Refractory Acute Myeloid Leukemia (R/R AML): An Overview
Relapsed/refractory acute myeloid leukemia (AML) is a devastating disease with a poor prognosis and represents a major unmet medical need. The prognosis of relapsed acute myeloid leukemia (AML) is poor and treatment is challenging. The signs and symptoms of acute myeloid leukemia (AML) are common to other, less serious illnesses. It is common for people with AML to feel a loss of well-being because of the underproduction of normal bone marrow cells.
Symptoms of a low red blood cell count (called “anemia”) include Fatigue, weakness, shortness of breath during normal physical activities, lightheadedness, dizziness or faintness, headaches, and pale complexion. Other general symptoms of AML include: Loss of appetite, unexplained weight loss, discomfort in bones or joints, fullness or swelling in the abdomen, due to an enlarged spleen or liver.
When considering treatment options for patients with relapsed/refractory AML, patient- and disease-related factors [e.g., age, comorbidities, performance status, cytogenetic and molecular abnormalities, prior lines of chemotherapy, history of prior allogeneic hematopoietic cell transplant (allo-HCT), and time to relapse after previous complete remission (CR)] should be carefully evaluated.
Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) Market Key Facts:
-
According to the Surveillance, Epidemiology, and End Results (SEER) study program, the rate of new cases of R/R Acute Myeloid Leukemia was 4.3 per 100,000 men and women per year in the United States. The death rate was 2.7 per 100,000 men and women per year. These rates are age-adjusted and based on 2014–2018 cases and 2015–2019 deaths.
-
According to data from the Global Burden of Disease Study 2017, among the EU5 countries, the UK has the highest prevalence of AML, at more than 5,000 cases, while Spain has the lowest at under 2,300 cases.
-
In a retrospective study by Matsunaga et al. (2012) in Japan, 221 patients (211 adults and 10 children) were diagnosed with AML, indicating an incidence of AML of 3.2 per 100,000 per year.
Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Relapsed/Refractory Acute Myeloid Leukemia pipeline therapies. It also thoroughly assesses the R/R AML market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the market trend for each marketed R/R AML drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted Relapsed/Refractory Acute Myeloid Leukemia epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted R/R AML epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.
The Report Covers the Relapsed/Refractory Acute Myeloid Leukemia Epidemiology, Segmented as -
-
Total Incident Cases of R/R AML in the 7MM [2019–2032]
-
Gender-specific Cases of R/R AML in the 7MM [2019–2032]
-
Age-specific Cases of R/R AML in the 7MM [2019–2032]
-
Mutation-specific Cases of R/R AML in the 7MM [2019–2032]
Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the R/R AML market or expected to be launched during the study period. The analysis covers the Relapsed/Refractory Acute Myeloid Leukemia market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Relapsed/Refractory Acute Myeloid Leukemia drugs based on their sale and market share.
The report also covers the R/R AML pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Relapsed/Refractory Acute Myeloid Leukemia companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Relapsed/Refractory Acute Myeloid Leukemia Market Will Evolve and Grow by 2032 @
https://www.delveinsight.com/sample-request/relapsed-refractory-acute-myeloid-leukemia-market
Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) Therapeutics Analysis
Several major pharma and biotech companies are developing therapies for Relapsed/refractory acute myeloid leukemia (AML). Currently, Ascentage Pharma is leading the therapeutics market with its relapsed/refractory acute myeloid leukemia (AML) drug candidates in the most advanced stage of clinical development.
Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) Actively Working in the Therapeutics Market Include
-
Ascentage Pharma
-
Cullinan Oncology
-
Kronos Bio
-
Maxinovel Pharmaceuticals
-
AB Science
-
CicloMed
-
Karyopharm Therapeutics
-
Antengene Corporation
-
GlycoMimetics
-
Servier
-
Novartis
-
ImmunoGen
And Many Others
Emerging and Marketed Relapsed/Refractory Acute Myeloid Leukemia Therapies Covered in the Report Include:
-
APG-2575: Ascentage Pharma
-
CLN 049: Cullinan Oncology
-
Lanraplenib: Kronos Bio
-
Crenolanib: Arog Pharmaceuticals
-
Olutasidenib: Forma Therapeutics
-
Annamycin: Moleculin
And Many More
The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @
https://www.delveinsight.com/sample-request/relapsed-refractory-acute-myeloid-leukemia-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Relapsed/Refractory Acute Myeloid Leukemia Competitive Intelligence Analysis
4. Relapsed/Refractory Acute Myeloid Leukemia Market Overview at a Glance
5. Relapsed/Refractory Acute Myeloid Leukemia Disease Background and Overview
6. Relapsed/Refractory Acute Myeloid Leukemia Patient Journey
7. Relapsed/Refractory Acute Myeloid Leukemia Patient Population and Epidemiology Trends (In the US, EU5, and Japan)
8. Relapsed/Refractory Acute Myeloid Leukemia Treatment Algorithm, Current Treatment, and Medical Practices
9. Relapsed/Refractory Acute Myeloid Leukemia Unmet Needs
10. Key Endpoints of Relapsed/Refractory Acute Myeloid Leukemia Treatment
11. Relapsed/Refractory Acute Myeloid Leukemia Marketed Therapies
12. Relapsed/Refractory Acute Myeloid Leukemia Emerging Drugs and Latest Therapeutic Advances
13. Relapsed/Refractory Acute Myeloid Leukemia Seven Major Market Analysis
14. Attribute Analysis
15. Relapsed/Refractory Acute Myeloid Leukemia Market Outlook (In US, EU5, and Japan)
16. Relapsed/Refractory Acute Myeloid Leukemia Companies Active in the Market
17. Relapsed/Refractory Acute Myeloid Leukemia Access and Reimbursement Overview
18. KOL Views on the Relapsed/Refractory Acute Myeloid Leukemia Market
19. Relapsed/Refractory Acute Myeloid Leukemia Market Drivers
20. Relapsed/Refractory Acute Myeloid Leukemia Market Barriers
21. Appendix
22. DelveInsight Capabilities
23. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download the Sample PDF to Learn More About the Key Offerings of the Report @
https://www.delveinsight.com/sample-request/relapsed-refractory-acute-myeloid-leukemia-market
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports by DelveInsight
"Diabetic Eye Disease Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Diabetic Eye Disease market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Diabetic Eye Disease market.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
